Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
about
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsFourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignanciesJuvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantationTreatment of chronic graft-versus-host disease in 2011Graft-versus-host disease: why have we not made more progress?Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignanciesCurrent and emerging strategies for the prevention of graft-versus-host diseaseThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseAlternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome.A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantationPost-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantationThe effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML.Transplantation immunology: solid organ and bone marrow.Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.Current issues in chronic graft-versus-host disease.High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.Graft-versus-host disease: state of the science.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrLess graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantationOutcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCTMulti-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningReduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignanciesHave we made progress in the management of chronic graft-vs-host disease?Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancyLow-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.How we treat chronic graft-versus-host disease.Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemiaPrior exposure to imatinib does not impact outcome of allogeneic hematopoietic transplantation for chronic myeloid leukemia patients: a single-center experience in chinaGraft-versus-host disease prophylaxis after transplantation: a network meta-analysis.Treatment of chronic graft-versus-host disease: Past, present and future.
P2860
Q24200813-880EEC41-24A1-4FBE-9706-BB6EC3B7912DQ26830130-9F160F35-53E1-4CE3-B811-C76C6DD2A4B0Q26851000-448B3B0B-77DD-42E4-A59B-03EF874A4C43Q26851433-00A93526-7C78-43C1-9EB6-36DCC327B7F6Q27012940-CC8D2801-707C-4997-8DA6-E8B912317AB1Q27014857-FF258DEB-0FDF-415A-84EE-6F7AE1229447Q27016541-7510EA8E-88CA-4B66-B74B-744C124C3A1FQ28076264-4DFA6FEC-130D-48D6-BB67-12BAA7B9C64FQ30252339-225B19DB-13BE-4E44-B3D9-FBCE71F574CBQ33441641-D939E0B4-FE44-4341-90A9-29E796793F31Q33573529-EAFC3AC4-AC88-46BC-BDC3-016AB402FE1CQ33764825-4185A5BF-7410-4EA5-BFAC-F5F45A7BC717Q33797194-1FAA0CBE-988B-4DAE-9FDA-7E9B43D0E09AQ33803804-365E2548-B48E-4336-A95E-C45CCEB6B706Q33822026-7CD66EC6-9F42-435E-A3C6-B328D442D1C5Q33917187-C6481CDF-4AF7-4953-AF90-6E3679B9754EQ33950015-51B16539-58A5-468C-AD12-447A6F6FA73EQ33977923-7258021E-5CB3-4A2D-B188-0B2FA8041492Q34044024-07741973-9AB0-4128-AC22-D0EFFEC15C1AQ34134601-12950706-B674-4C8C-BF2E-9808E1678EB9Q34240410-9AD40E9E-A0B1-42DF-A910-2D26CD23ECAFQ34279672-9B3FD670-C3A7-4BF6-A9E3-FD859141C886Q34348102-BA18D05F-86AB-466F-807A-EC5008C28100Q34398411-0B132D94-3F2F-487F-935B-47666A146916Q34402494-DFB73461-349C-404B-95B1-CD61564F8ACBQ34463645-5AD9B1A7-6107-4D49-8395-B10F675DC92DQ34644980-68D1F8A4-BDBE-4B95-8057-E38234011722Q34684038-83C844D6-50F4-40FE-B9EA-94ECE0956375Q34707280-7B2BD49A-E833-4EF3-823D-9687905BFAF0Q34749391-3E40FABD-C8D9-40C2-8E8F-8462EE7139DEQ34860077-8F53ADF8-44A3-4114-B7FF-409F73DB03C4Q35004923-4CB20EDF-700A-408C-BAA5-A097BE641C71Q35078368-3A6A89CA-D5F3-4C3B-A4FE-89329F0003A5Q35083281-A01488F8-19C6-4B6D-AD2F-80398E5A5180Q35199893-B8CC5A1A-BBAE-41E8-9E37-E6569A5FFDE2Q35317371-4A30915D-4B46-40BA-B722-9621E88DC54FQ35321329-13A298A4-A49C-4D07-98D5-804D11B71E9AQ35480678-860FCC54-E571-4DB4-962E-E215FC67C8F6Q35499395-12465975-0BCB-436E-8224-C6F9590FE452Q35524687-387344EB-CF80-4BA4-943E-B0E65DEAFEBE
P2860
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@ast
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@en
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@nl
type
label
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@ast
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@en
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@nl
prefLabel
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@ast
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@en
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@nl
P2093
P50
P1433
P1476
Standard graft-versus-host dis ...... el, multicentre phase 3 trial.
@en
P2093
ATG-Fresenius Trial Group
Axel R Zander
Claudia Schmoor
Dominik A Heim
Ernst Holler
Hans-Jochem Kolb
Hartmut Bertz
Hellmut D Ottinger
Jiri Mayer
Johan A Maertens
P304
P356
10.1016/S1470-2045(09)70225-6
P577
2009-08-18T00:00:00Z